Clinical Trial · NCT01916148

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Overview

This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a focal lesion of hyperinsulinism and determine the location in patients with congenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.

Sponsor

Children's Hospital of Philadelphia

Contacts

Lisa States, MD (PRINCIPAL_INVESTIGATOR)

Lisa States, MD (CONTACT)

states@chop.edu

267-425-7146

Susan Becker, RN, BSN, CCRC (CONTACT)

beckers@chop.edu

267-426-0269

ClinicalTrials.gov

NCT01916148

Drug / Compound

DOPA

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Subjects who are eligible for pancreatic surgery regardless of prior pancreatic surgery

Exclusion

Subjects who are not a candidate for pancreatic surgery